Assessment of the Anti-inflammatory Effects of Norflo Oro in Acute Relapses of HLA-B27 Associated Autoimmune Uveitis

• Status: Active, not recruiting
• Trial end date: 2021-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to explore the efficacy of Norflo Oro in the treatment of relapsing autoimmune uveitis (RAU), measured as a long term reduction of the frequency and the severity of relapses, in patients with HLA-B27 associated uveitis, under conditions of routine medical practice. The reduction of the mean number of relapses per patient between the year before study treatment and the study period will also be assessed.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eye Pharma
• Collaborator: Bascom Palmer Eye Institute
• Treatments: Anti-Inflammatory Agents

Criteria

Inclusion Criteria:

• Clinical diagnosis of HLA-B27 positive related uveitis in non- acute phase

• At least one autoimmune uveitis relapse

Exclusion Criteria:

• Use of supplements (nutraceuticals) or systemic therapy for uveitis with anti-inflammatory immunosuppressive or biological drugs within last 30 days

• Anticipated need for systemic anti-inflammatory treatment during the study

• Use of intravitreal peribulbar, sub-tenon, periocular injection in the previous 6 months

• Long-term treatment with a systemic anti-inflammatory, immune suppressant drugs

• Woman taking hormonal contraceptives, pregnant or breastfeeding.